

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ab&B Bio-Tech CO., LTD. JS

江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT

COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT)

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the “**Company**” or “**Ab&B Bio-Tech**”, together with its subsidiary, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Group has recently initiated Phase I and Phase II clinical trials of the Group’s self-developed Recombinant RSV vaccine (CHO cell) (Adjuvant). We obtained Investigational New Drug approval from the National Medical Products Administration of the People’s Republic of China for our Recombinant RSV vaccine (CHO cell) (Adjuvant) in August 2025.

Respiratory Syncytial Virus (“**RSV**”), as a highly contagious RNA virus, is one of the significant pathogens responsible for respiratory tract infections in infants, the elderly and immunocompromized individuals. Clinically, it primarily manifests as symptoms of acute respiratory infection, with lower respiratory tract infection being the predominant form. Severe cases can be life-threatening. In China, RSV ranked second among pathogens causing acute respiratory infections in adults and first among those in children from 2009 to 2019, according to Chinese Center for Disease Control and Prevention. Due to the current lack of effective clinical treatment options, supportive care is mainly relied upon to manage acute infections, making vaccination the preferred clinical solution for the prevention and control of RSV.

Our Recombinant RSV Vaccine (CHO cell) (Adjuvant) is developed based on CHO cells and expresses the modified pre-F protein. After extensive screening, we have obtained high-yield monoclonal cell lines capable of stably expressing the pre-F protein. In our preclinical studies, it demonstrated higher pre-F expression levels, better thermal stability and superior immunogenicity than the marketed recombinant RSV vaccines. According to their previously published results, the expression levels of the pre-F protein in marketed recombinant RSV vaccines range from 600 mg/L to 800 mg/L. In contrast, our high-yield cell line produces pre-F protein at approximately 1,000 mg/L to 1,500 mg/L. Preclinical studies showed that after storage at 40°C for 14 days, our pre-F protein retains over 95% activity, while marketed products decrease to around 50% activity. Due to its stability, our product is formulated as a liquid rather than a lyophilized form, unlike the approved products. In our preclinical immunogenicity study conducted in mice, our vaccine candidate achieved a much higher GMT of neutralizing antibodies than a similar marketed product. It also demonstrated a good safety profile in our toxicity studies and active systemic anaphylaxis test.

About Ab&B Bio-Tech

Ab&B Bio-Tech is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines adopting new technical methods. In formulating our pipeline, we closely track global trends in infectious disease incidence and vaccine R&D, with a strategic focus on premium vaccines, aiming to replace traditional vaccines and imported vaccines in China and establish our presence in international markets. Our range of products include but are not limited to, the quadrivalent subunit influenza vaccine, the trivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, along with other vaccine candidates.

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that Recombinant RSV vaccine (CHO cell) (Adjuvant) will ultimately be successfully developed and marketed by the Company.

Continued Suspension of Trading

Trading in the H Shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on Wednesday, April 1, 2026 and will remain suspended until further notice.

Further announcement(s) will be made by the Company to keep the Shareholders and potential investors informed of any material development in this regard as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai

Executive Director, chairman of our Board and general manager

Hong Kong, May 13, 2026

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Mr. LI Jianjun and Mr. CHEN Chengbei as independent non-executive Directors.